ScholarLink (思领科)
错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Circulating free insulin-like growth factor-I and prostate cancer: a case-control study nested in the European prospective investigation into cancer and nutrition

  • 期刊论文

  • 出版模式：

    开放获取

  • 发表日期：

    2024年6月3日

查看全文
  • Tuck Seng Cheng,
  • Urwah Noor,
  • Eleanor Watts,
  • Michael Pollak,
  • Ye Wang,
  • James McKay,
  • Joshua Atkins,
  • Giovanna Masala,
  • Maria-Jose Sánchez,
  • Antonio Agudo,
  • Jesús Castilla,
  • Dagfinn Aune,
  • Sandra M. Colorado-Yohar,
  • Luca Manfredi,
  • Marc J. Gunter,
  • Valeria Pala,
  • Andreas Josefsson,
  • Timothy J. Key,
  • Karl Smith-Byrne,
  • Ruth C. Travis

摘要

Background

Circulating total insulin-like growth factor-I (IGF-I) is an established risk factor for prostate cancer. However, only a small proportion of circulating IGF-I is free or readily dissociable from IGF-binding proteins (its bioavailable form), and few studies have investigated the association of circulating free IGF-I with prostate cancer risk.

Methods

We analyzed data from 767 prostate cancer cases and 767 matched controls nested within the European Prospective Investigation into Cancer and Nutrition cohort, with an average of 14-years (interquartile range = 2.9) follow-up. Matching variables were study center, length of follow-up, age, and time of day and fasting duration at blood collection. Circulating free IGF-I concentration was measured in serum samples collected at recruitment visit (mean age 55 years old; standard deviation = 7.1) using an enzyme-linked immunosorbent assay (ELISA). Conditional logistic regressions were performed to examine the associations of free IGF-I with risk of prostate cancer overall and subdivided by time to diagnosis (≤ 14 and > 14 years), and tumor characteristics.

Results

Circulating free IGF-I concentrations (in fourths and as a continuous variable) were not associated with prostate cancer risk overall (odds ratio [OR] = 1.00 per 0.1 nmol/L increment, 95% CI: 0.99, 1.02) or by time to diagnosis, or with prostate cancer subtypes, including tumor stage and histological grade.

Conclusions

Estimated circulating free IGF-I was not associated with prostate cancer risk. Further research may consider other assay methods that estimate bioavailable IGF-I to provide more insight into the well-substantiated association between circulating total IGF-I and subsequent prostate cancer risk.